Management of patients with atopic dermatitis undergoing systemic therapy during COVID‐19 pandemic in Italy: Data from the DA‐COVID‐19 registry

• DOI: 10.1111/all.14767
• Publication Date: 2021-02-14T03:04:10Z
• Authors: Andrea Chiricozzi; Marina Talamonti; Clara De Simone; Marco Galluzzo; Niccolò Gori; Gabriella Fabbrocini; Angelo Valerio Ma...; Giampiero Girolomoni; Annamaria Offidani; Maria Teresa Rossi; Luca Bianchi; Antonio Cristaudo; Maria Teresa Fierro; Luca Stingeni; Giovanni Pellacani; Giuseppe Argenziano; Annalisa Patrizi; Paolo Pigatto; Marco Romanelli; Paola Savoia; Pietro Rubegni; Caterina Foti; Nicola Milanesi; Anna Belloni Fortina; Maria Rita Bongiorno; Teresa Grieco; Sergio Di Nuzzo; Maria Concetta Fa...; Andrea Carugno; Alberico Motolese; Franco Rongioletti; Paolo Amerio; Riccardo Balestri; Concetta Potenza; Giuseppe Micali; Cataldo Patruno; Iris Zalaudek; Maurizio Lombardo; Claudio Feliciani; Lucia Di Nardo; Fabrizio Guarneri; Ketty Peris
• Keywords: Pandemic

Abstract Background Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID‐19) pandemic. Methods A national registry, named DA‐COVID‐19 involving 35 Italian dermatology units, was established order to evaluate impact COVID‐19 pandemic on adult AD treated with systemic medications phototherapy. Demographic clinical data were obtained at different timepoints by teledermatology pandemic, when regular visits not allowed due sanitary restrictions. Disease severity assessed both physician‐ patient‐reported assessment scores evaluating itch intensity, sleep disturbances, severity. Results total 1831 included, 1580/1831 (86.3%) continuing therapy Most dupilumab (86.1%, 1576/1831) that interrupted only 9.9% (156/1576) cases, while immunosuppressive compounds more frequently withdrawn. Treatment interruption decision patient, general practitioner, dermatologist 39.9% (114/286), 5.6% (16/286), 30.1% (86/286) respectively. Fear increased susceptibility SARS‐CoV‐2 infection (24.8%, 71/286) one main causes interruption. Sixteen (0.9%) resulted positive infection; 3 them (0.2%) hospitalized but no cases COVID‐related death occurred. Conclusions continued treatments COVID lockdown period, without high control, particularly dupilumab‐treated patients.